DNA RNA and Cells

23 June 2025

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

21 June 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA’s Annual Scientific Sessions

21 June 2025

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

20 June 2025

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

19 June 2025

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

18 June 2025

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

16 June 2025

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

16 June 2025

AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025

16 June 2025

HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China

16 June 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

15 June 2025

Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

14 June 2025

Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

13 June 2025

U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio’s Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma

13 June 2025

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

13 June 2025

Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology

13 June 2025

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

12 June 2025

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

12 June 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

12 June 2025

SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer

12 June 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

12 June 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee

12 June 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

12 June 2025

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

12 June 2025

Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease

12 June 2025

Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations

10 June 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

10 June 2025

ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

10 June 2025

Factor Bioscience to Unveil iMacrophages Engineered to Combat Solid Tumors at the ISSCR Annual Meeting

10 June 2025

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

10 June 2025

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World’s First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

TSLP Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review